Below is a detailed analysis of the quarterly data for Entero Healthcare Solutions Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 1,339.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,359.00 Cr. (Dec 2024) to 1,339.00 Cr., marking a decrease of 20.00 Cr..
For Expenses, as of Mar 2025, the value is 1,290.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,309.00 Cr. (Dec 2024) to 1,290.00 Cr., marking a decrease of 19.00 Cr..
For Operating Profit, as of Mar 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Dec 2024) to 49.00 Cr., marking a decrease of 1.00 Cr..
For OPM %, as of Mar 2025, the value is 4.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 4.00%.
For Other Income, as of Mar 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Dec 2024) to 7.00 Cr., marking a decrease of 1.00 Cr..
For Interest, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 10.00 Cr..
For Depreciation, as of Mar 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 8.00 Cr..
For Profit before tax, as of Mar 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Dec 2024) to 37.00 Cr., marking a decrease of 2.00 Cr..
For Tax %, as of Mar 2025, the value is 16.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Dec 2024) to 16.00%, marking a decrease of 9.00%.
For Net Profit, as of Mar 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Dec 2024) to 31.00 Cr., marking an increase of 2.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 5.91. The value appears strong and on an upward trend. It has increased from 5.85 (Dec 2024) to 5.91, marking an increase of 0.06.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 1:34 pm
Metric
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
1,350
1,773
2,522
3,300
3,922
5,096
Expenses
1,326
1,758
2,498
3,236
3,810
4,924
Operating Profit
23
15
24
64
112
172
OPM %
2%
1%
1%
2%
3%
3%
Other Income
5
11
4
6
14
40
Interest
13
20
29
49
66
42
Depreciation
12
16
20
24
25
31
Profit before tax
4
-11
-20
-4
36
139
Tax %
67%
42%
49%
201%
-12%
23%
Net Profit
1
-15
-29
-11
40
107
EPS in Rs
93.81
-1,550.90
-77.71
-28.12
8.99
21.80
Dividend Payout %
0%
0%
0%
0%
0%
0%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2020-2021
2021-2022
2022-2023
2023-2024
2024-2025
YoY Net Profit Growth (%)
-1600.00%
-93.33%
62.07%
463.64%
167.50%
Change in YoY Net Profit Growth (%)
0.00%
1506.67%
155.40%
401.57%
-296.14%
Entero Healthcare Solutions Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
Compounded Sales Growth
10 Years:
%
5 Years:
30%
3 Years:
26%
TTM:
30%
Compounded Profit Growth
10 Years:
%
5 Years:
152%
3 Years:
73%
TTM:
143%
Stock Price CAGR
10 Years:
%
5 Years:
%
3 Years:
%
1 Year:
5%
Return on Equity
10 Years:
%
5 Years:
%
3 Years:
%
Last Year:
6%
Last Updated: Unknown
No data available for the Balance Sheet data table.
Reserves and Borrowings Chart
Cash Flow
Month
Month
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Cash from Operating Activity +
-37
-69
-35
-45
-37
-77
Cash from Investing Activity +
-203
-31
-162
-49
-704
220
Cash from Financing Activity +
217
89
211
73
863
-74
Net Cash Flow
-23
-11
14
-21
122
69
Free Cash Flow Chart
Financial Efficiency Indicators
Month
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Debtor Days
50
54
57
57
Inventory Days
54
49
41
43
Days Payable
22
22
25
24
Cash Conversion Cycle
82
81
73
77
Working Capital Days
84
79
72
71
ROCE %
1%
5%
7%
Financial Efficiency Indicators Chart
Share Holding Pattern
Month
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Promoters
52.44%
52.44%
52.44%
52.44%
FIIs
23.30%
23.32%
23.82%
22.20%
DIIs
2.28%
2.06%
7.73%
8.78%
Public
21.99%
22.18%
16.02%
16.59%
No. of Shareholders
80,864
66,400
36,767
33,172
Shareholding Pattern Chart
No. of Shareholders
This stock is not held by any mutual fund.
ROCE Trend
EPS Trend
Key Financial Ratios
Month
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
FaceValue
10.00
10.00
10.00
10.00
10.00
Basic EPS (Rs.)
21.80
10.81
-3.10
-9.22
-5.29
Diluted EPS (Rs.)
21.76
10.81
-3.10
-9.22
-5.29
Cash EPS (Rs.)
31.75
14.90
31.94
-25.16
92.20
Book Value[Excl.RevalReserv]/Share (Rs.)
396.28
377.38
-160.39
-144.87
-3005.20
Book Value[Incl.RevalReserv]/Share (Rs.)
396.28
377.38
-160.39
-144.87
-3005.20
Revenue From Operations / Share (Rs.)
1171.23
901.80
8025.80
6550.82
177973.70
PBDIT / Share (Rs.)
48.51
29.03
169.07
75.12
2547.60
PBIT / Share (Rs.)
41.45
23.28
110.13
23.81
920.00
PBT / Share (Rs.)
31.89
8.17
-8.97
-51.46
-1083.80
Net Profit / Share (Rs.)
24.69
9.15
-27.00
-76.46
-1535.40
NP After MI And SOA / Share (Rs.)
21.79
8.99
-28.11
-77.71
-1553.70
PBDIT Margin (%)
4.14
3.21
2.10
1.14
1.43
PBIT Margin (%)
3.53
2.58
1.37
0.36
0.51
PBT Margin (%)
2.72
0.90
-0.11
-0.78
-0.60
Net Profit Margin (%)
2.10
1.01
-0.33
-1.16
-0.86
NP After MI And SOA Margin (%)
1.86
0.99
-0.35
-1.18
-0.87
Return on Networth / Equity (%)
5.49
2.38
0.00
0.00
0.00
Return on Capital Employeed (%)
9.70
5.80
6.61
1.38
1.68
Return On Assets (%)
3.50
1.66
-0.88
-2.65
-1.86
Long Term Debt / Equity (X)
0.00
0.02
-0.45
-0.64
0.00
Total Debt / Equity (X)
0.17
0.16
-5.45
-4.92
-4.46
Asset Turnover Ratio (%)
2.02
2.15
2.71
2.57
0.00
Current Ratio (X)
2.46
3.34
1.64
1.84
2.19
Quick Ratio (X)
1.68
2.64
1.09
1.17
1.35
Interest Coverage Ratio (X)
5.07
1.92
1.42
0.99
1.27
Interest Coverage Ratio (Post Tax) (X)
3.58
1.61
0.77
-0.01
0.23
Enterprise Value (Cr.)
5029.50
3669.42
0.00
0.00
0.00
EV / Net Operating Revenue (X)
0.98
0.93
0.00
0.00
0.00
EV / EBITDA (X)
23.83
29.06
0.00
0.00
0.00
MarketCap / Net Operating Revenue (X)
0.97
1.09
0.00
0.00
0.00
Price / BV (X)
2.87
2.62
0.00
0.00
0.00
Price / Net Operating Revenue (X)
0.97
1.09
0.00
0.00
0.00
EarningsYield
0.01
0.01
0.00
0.00
0.00
After reviewing the key financial ratios for Entero Healthcare Solutions Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 21.80. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.80, marking an increase of 10.99.
For Diluted EPS (Rs.), as of Mar 25, the value is 21.76. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.76, marking an increase of 10.95.
For Cash EPS (Rs.), as of Mar 25, the value is 31.75. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 31.75, marking an increase of 16.85.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,171.23. It has increased from 901.80 (Mar 24) to 1,171.23, marking an increase of 269.43.
For PBDIT / Share (Rs.), as of Mar 25, the value is 48.51. This value is within the healthy range. It has increased from 29.03 (Mar 24) to 48.51, marking an increase of 19.48.
For PBIT / Share (Rs.), as of Mar 25, the value is 41.45. This value is within the healthy range. It has increased from 23.28 (Mar 24) to 41.45, marking an increase of 18.17.
For PBT / Share (Rs.), as of Mar 25, the value is 31.89. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 31.89, marking an increase of 23.72.
For Net Profit / Share (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has increased from 9.15 (Mar 24) to 24.69, marking an increase of 15.54.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 21.79. This value is within the healthy range. It has increased from 8.99 (Mar 24) to 21.79, marking an increase of 12.80.
For PBDIT Margin (%), as of Mar 25, the value is 4.14. This value is below the healthy minimum of 10. It has increased from 3.21 (Mar 24) to 4.14, marking an increase of 0.93.
For PBIT Margin (%), as of Mar 25, the value is 3.53. This value is below the healthy minimum of 10. It has increased from 2.58 (Mar 24) to 3.53, marking an increase of 0.95.
For PBT Margin (%), as of Mar 25, the value is 2.72. This value is below the healthy minimum of 10. It has increased from 0.90 (Mar 24) to 2.72, marking an increase of 1.82.
For Net Profit Margin (%), as of Mar 25, the value is 2.10. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 24) to 2.10, marking an increase of 1.09.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.86. This value is below the healthy minimum of 8. It has increased from 0.99 (Mar 24) to 1.86, marking an increase of 0.87.
For Return on Networth / Equity (%), as of Mar 25, the value is 5.49. This value is below the healthy minimum of 15. It has increased from 2.38 (Mar 24) to 5.49, marking an increase of 3.11.
For Return on Capital Employeed (%), as of Mar 25, the value is 9.70. This value is below the healthy minimum of 10. It has increased from 5.80 (Mar 24) to 9.70, marking an increase of 3.90.
For Return On Assets (%), as of Mar 25, the value is 3.50. This value is below the healthy minimum of 5. It has increased from 1.66 (Mar 24) to 3.50, marking an increase of 1.84.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.17, marking an increase of 0.01.
For Asset Turnover Ratio (%), as of Mar 25, the value is 2.02. It has decreased from 2.15 (Mar 24) to 2.02, marking a decrease of 0.13.
For Current Ratio (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 3.34 (Mar 24) to 2.46, marking a decrease of 0.88.
For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.64 (Mar 24) to 1.68, marking a decrease of 0.96.
For Interest Coverage Ratio (X), as of Mar 25, the value is 5.07. This value is within the healthy range. It has increased from 1.92 (Mar 24) to 5.07, marking an increase of 3.15.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.58. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 3.58, marking an increase of 1.97.
For Enterprise Value (Cr.), as of Mar 25, the value is 5,029.50. It has increased from 3,669.42 (Mar 24) to 5,029.50, marking an increase of 1,360.08.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.93 (Mar 24) to 0.98, marking an increase of 0.05.
For EV / EBITDA (X), as of Mar 25, the value is 23.83. This value exceeds the healthy maximum of 15. It has decreased from 29.06 (Mar 24) to 23.83, marking a decrease of 5.23.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has increased from 2.62 (Mar 24) to 2.87, marking an increase of 0.25.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Entero Healthcare Solutions Ltd as of June 26, 2025 is: 954.98
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of June 26, 2025, Entero Healthcare Solutions Ltd is Overvalued by 16.45% compared to the current share price 1,143.00
Intrinsic Value of Entero Healthcare Solutions Ltd as of June 26, 2025 is: 713.24
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of June 26, 2025, Entero Healthcare Solutions Ltd is Overvalued by 37.60% compared to the current share price 1,143.00
Last 5 Year EPS CAGR: -25.31%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Entero Healthcare Solutions Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 5.49% (Industry Average ROE: 15.19%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 52.4 (Industry average Stock P/E: 103.22)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.17
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Entero Healthcare Solutions Ltd. is a Public Limited Listed company incorporated on 10/01/2018 and has its registered office in the State of Haryana, India. Company's Corporate Identification Number(CIN) is L74999HR2018PLC072204 and registration number is 072204. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company's Total Operating Revenue is Rs. 408.67 Cr. and Equity Capital is Rs. 43.51 Cr. for the Year ended 31/03/2025.
INDUSTRY
ADDRESS
CONTACT
Pharmaceuticals
Plot No. I-35, Building - B, Industrial Area, Phase - I, Faridabad Haryana 121003
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Entero Healthcare Solutions Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
